Longidase, lyophilizate 3000me 5 pcs

The drug with proteolytic activity. It has enzymatic proteolytic (hyaluronidase) activity with prolonged action, immunomodulatory, chelating, antioxidant and anti-inflammatory action.

The prolonged action of the drug is carried out due to covalent binding of the enzyme with physiologically active high-molecular carrier (activated derivative of N-oxide poly-1.4-ethylenpiperazine) which has its own pharmacological activity: it has immunomodulatory, detoxifying and antioxidant action.

The presence of a covalent bond greatly increases the resistance of the enzyme to denaturing influences and the influence of inhibitors. The enzymatic activity of Longidase is maintained when heated to 37°C for 20 days, while native hyaluronidase loses its activity in the same conditions within a day.

The covalent bond provides the simultaneous local presence of the hydrolytic enzyme and a carrier capable of binding the released enzyme inhibitors and stimulators of collagen synthesis (iron ions, copper ions, heparin). Due to the above properties Longidase has not only the ability to depolymerize the matrix of connective tissue in fibrotic-granulomatous formations, but also suppresses the reverse regulatory reaction aimed at the synthesis of components of connective tissue.

The specific substrate of testicular hyaluronidase is glucosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C 1 acetylglucosamine and C 4 glucuronic or induronic acids), under the influence of hyaluronidase glucosaminoglycans lose their main properties (viscosity, ability to bind water, metal ions). The formation of collagen proteins into fibers is also impeded, the permeability of tissue barriers increases, the movement of fluid in the intercellular space is facilitated, and the elasticity of connective tissue increases. The action of the drug leads to reduction of tissue edema, flattening of scars, increase of joint movement, reduction of contractures and adhesions and prevention of their formation.

The preparation decreases manifestations of acute phase of inflammatory process, regulates (increases or decreases depending on initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor), increases resistance of organism to infection and increases humoral immune response.

Longidaza has no antigenic properties and no mitogenic, polyclonal activity; it has no allergic, mutagenic, embryotoxic, teratogenic and carcinogenic action.

Indications

The drug is prescribed to adults in the complex therapy for the treatment and prevention of diseases accompanied by connective tissue hyperplasia.

In gynecology:

In urology:

In surgery:

In dermatology and cosmetology:

In pulmonology and phthisiology:

In orthopedics:

To increase bioavailability:

Active ingredient

Composition

1 vial contains longidase with hyaluronidase activity of 3000 IU

supplement:

Mannitol – up to 20 mg

How to take, the dosage

Longidase is applied by injection (in the vicinity of the lesion or under the scar tissue) or intravenously at a dose of 3000 IU in a course of 5 to 25 injections (depending on the disease) with an interval between injections of 3 to 10 days.

The method of administration is chosen by the doctor depending on the diagnosis, the severity of the disease, the clinical course and the age of the patient. If necessary, it is recommended to repeat the course in 2-3 months.

In case of treatment of diseases accompanied by severe chronic productive process in the connective tissue, after the standard course the long-term maintenance therapy with Longidase is recommended with 10-14-day intervals between injections.

In order to increase bioavailability of the drugs and diagnostic agents a dose of 1500 IU is recommended with 10-15 minutes prior I/m or p/c injection in the same place as the main drug.

Dilution

The solvent in the vial or ampoule should be introduced slowly, wait 2-3 minutes, mix gently, without shaking to avoid foaming the protein. Prepared solution for parenteral administration should not be stored. It should not be administered by injection!

Recommended regimens for prevention and treatment

For prevention of adhesions and rough scarring after surgical operations on the abdominal and pelvic organs, the drug is given in the dosage of 3000 ME once in 3 days with 5 injections. If necessary, the drug can be continued for a total course of up to 10 injections once every 5 days.

For treatment

in gynecology:

In urology:

in surgery:

in dermatovenerology, cosmetology:

in pulmonology and phthisiology:

in orthopedics:

To increase bioavailability: when co-administered p / n or i / m with diagnostic or medicinal products (antibiotics, chemopreparations, anesthetics and others), Longidase is administered 10-15 minutes in advance in a dose of 1500 ME in the same way and in the same place as the main drug.

Interaction

Longidase is compatible with antibiotics, antiviral, antifungal and antihistamines, bronchodilators, cytostatics, GCS.

When used together it increases bioavailability of medicines and speeds up the onset of analgesia when using local anesthetics.

Special Instructions

The drug should not be injected into an area of infectious lesion, acute inflammation or tumor.

Contraindications

With caution prescribe the drug in acute renal failure, pulmonary bleeding.

Side effects

Local reactions: soreness at the injection site; in some cases – skin hyperemia and tissue swelling at the injection site.

Others: rare allergic reactions.

All adverse reactions disappear after 48-72 hours.

Overdose

There are currently no reported cases of overdose of Longidase.

Pregnancy use